Specifically targeted gene therapy for small-cell lung cancer

Expert Rev Anticancer Ther. 2009 Apr;9(4):437-52. doi: 10.1586/era.09.10.

Abstract

Small-cell lung cancer (SCLC) is a highly malignant disease with poor prognosis. Hence, there is great demand for new therapies that can replace or supplement the current available treatment regimes. Gene therapy constitutes a promising strategy and relies on the principle of introducing exogenous DNA into malignant cells causing them to die. Since SCLC is a highly disseminated malignancy, the gene therapeutic agent must be administered systemically, obligating a high level of targeting of tumor tissue and the use of delivery vehicles designed for systemic circulation of the therapeutic DNA. This review describes and discusses the current status of the application of gene therapy in relation to SCLC.

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Small Cell / drug therapy
  • Carcinoma, Small Cell / genetics
  • Carcinoma, Small Cell / therapy*
  • Cell Line, Tumor
  • Combined Modality Therapy
  • DNA, Recombinant / therapeutic use
  • Drug Delivery Systems
  • Drug Design
  • Genes, Synthetic
  • Genes, Transgenic, Suicide
  • Genes, Tumor Suppressor
  • Genetic Therapy*
  • Genetic Vectors / therapeutic use
  • Humans
  • Liposomes / administration & dosage
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / therapy*
  • Mice
  • Promoter Regions, Genetic
  • Transcription, Genetic
  • Xenograft Model Antitumor Assays

Substances

  • DNA, Recombinant
  • Liposomes